BeOne
Rewriting the Oncology Playbook
John V. Oyler, Co-Founder, Chairman & CEO
Next-generation Oncology
Next-generation Oncology refers to advanced cancer care and innovation driven by precision medicine, AI-powered diagnostics, genomic profiling, targeted therapeutics, immunotherapy, and data-led treatment strategies. The category recognises organisations transforming oncology through breakthrough technologies, personalised patient outcomes, accelerated drug development, and integrated digital health solutions that redefine modern cancer prevention, diagnosis, and treatment.
Solutions
Cancer doesn’t discriminate and neither should access to care. A disease that touches millions of lives every year; cancer challenges not just patients, but families, caregivers, and entire communities. Solving for it requires a collective ambition—a global coalition of clinicians, researchers, pharmaceutical leaders, and advocates. In this fast-evolving field, where innovation often outpaces access, BeOne Medicines stands apart: a next-generation global oncology company not just discovering breakthrough treatments, but ensuring they reach the people who need them most.
State of Industry
Laboratories in the Age of AI and Advanced Diagnostics
Laboratory science is rapidly transforming through technological innovation, redefining research, diagnostics, and data management with a focus on precision, efficiency, and interconnectedness. The overarching trend is a move towards highly integrated, intelligent, and sustainable laboratory environments, fundamentally altering the scientific discovery pipeline.
Deep Dive
Choosing a Gold-Standard Oncology Partner
Cancer programs now operate at the intersection of scientific innovation, access demands and financial discipline. For executives evaluating next-generation oncology partners, the key question is no longer simply whether a company can develop promising science. The more important issue is whether that science can move efficiently through development, manufacturing, evidence generation and market access in a way that broadens patient reach without creating unnecessary cost or delay.
Leadership Perspective
Vertex Pharmaceuticals
The Impact of AI on FP&A in the Life Sciences Sector
Lina Parra Cartagena, Associate Director of Finance - Operations
Lina Parra Cartagena is a seasoned FP&A professional with over 14 years of experience in corporate, commercial and operations finance across France, Mexico, Colombia, Spain and the U.S. She has worked in Consumer Goods and Pharmaceuticals, speaks four languages and excels in building FP&A teams by streamlining processes and fostering automation.
